EGFR and melanoma: Furthermore, the most potent EGFR inhibitors will be tested for their inhibitory effect against mutant-type EGFR (EGFRT790M), and the most potent anti-BRAF agents will be tested for their anticancer effect against the LOX-IMVI melanoma cell line, which has BRAFV600E kinase overexpression.